

4<sup>th</sup> October 2022

BSE LIMITED  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai – 400001

Dear Sir/Madam,

**Sub.: Increase in volume**  
**Scrip Code: BSE – AJANTPHARM 532331**

We refer to your email L/SURV/ONL/PV/IJ/ 2022-2023 / 225 dated 04<sup>th</sup> October 2022 seeking clarification w.r.t. significant increase in volume of securities of our Company.

In this regard we hereby clarify that as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we have timely disclosed to the Exchanges all the information/events that have a bearing on the operations/performance of the Company and no such material information /event have remained to be disclosed.

It appears that the significant increase in the volume of securities of the Company is purely driven by market dynamics and is not attributed to any material information or event that have bearing on the price/volume of the securities of the Company. We see on the website of NSE that yesterday there was bulk deal in the shares of our Company whereunder ISHARES CORE MSCI EMERGING MARKETS ETF have bought 91,742 shares and ISHARES CORE EMERGING MARKETS MAURITIUS CO have sold 91,742 shares.

Since the shares of the Company are freely traded on the Stock Exchange, the Company is unable to comment on the movement in share price of the Company.

The Company has always abided by and complied with all the disclosures and regulatory requirements and is meticulously following all the Corporate Governance norms.

Yours faithfully,

**GAURANG SHAH**  
*VP – Legal & Company Secretary*